Compare Neurocrine Biosciences Inc (NBIX) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs AT&T Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155.7 (market cap $15.77B), while AT&T Inc. trades at $25.31 (market cap $172.34B). The key difference: AT&T Inc. is far larger — about 10.9× Neurocrine Biosciences Inc's market cap, and AT&T Inc. pays a 4.41% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | T | |
|---|---|---|
Market Cap | $15.77B | $172.34B |
Sector | Health | Media |
52-Week High | $185.50 | $29.62 |
52-Week Low | $123.10 | $20.49 |
Enterprise Value | $15.78B | $317.66B |
Dividend Yield | — | 4.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
AT&T (T) trades at $25.61, down 0.21% over 24 hours, with a bullish technical signal driven by moving averages. The stock shows strong fundamentals with a P/E of 8.3, net income margin of 16.94%, and consistent earnings beats. Recent news highlights fiber and wireless growth strategies, including a partnership with Amazon for satellite broadband. Cash flow improved to $15.12B in 2025, and the balance sheet reflects reduced debt-to-asset ratio of 32.59% in 2024.
Outlook: AT&T offers value with low valuation multiples and dividend stability, but faces risks from high debt and competitive pressures. Analyst consensus is mixed with a $27.69 price target, suggesting moderate upside. Key opportunities include fiber expansion and AI integration, while execution on growth initiatives remains critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
